Lung adenocarcinoma patient with an EGFR kinase domain duplication (KDD) and the response to icotinib

Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related morbidity and mortality worldwide (1). Epidermal growth factor receptor ( EGFR ) mutations, as driver oncogenes, were first identified in NSCLC in 2004 (2).